Clinical Trials
4
Active:1
Completed:0
Trial Phases
3 Phases
Phase 1:2
Phase 2:1
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (50.0%)Phase 2
1 (25.0%)Phase 3
1 (25.0%)[90Y]Y-PTT Endoradiotherapy in CNS Lymphoma Patients
- First Posted Date
- 2023-11-15
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Pentixapharm AG
- Target Recruit Count
- 15
- Registration Number
- NCT06132737
- Locations
- 🇩🇪
University Hospital Rechts der Isar, Munich, Bavaria, Germany
🇩🇪University Hospital Essen, Essen, Germany
[68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma
Phase 3
Active, not recruiting
- Conditions
- Marginal Zone Lymphoma
- Interventions
- Drug: [18F]Fluorodeoxyglucose
- First Posted Date
- 2023-11-09
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- Pentixapharm AG
- Target Recruit Count
- 148
- Registration Number
- NCT06125028
- Locations
- 🇦🇹
Medizinische Universität Innsbruck, Innsbruck, Austria
🇫🇷CHU de Bordeaux, Bordeaux, France
🇫🇷CHU La Timone, Marseille, France
[68Ga]Ga-PentixaFor PET Imaging in CNS Lymphoma Patients
- First Posted Date
- 2022-02-03
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Pentixapharm AG
- Target Recruit Count
- 1
- Registration Number
- NCT05222269
- Locations
- 🇩🇰
University Hospital Aalborg, Aalborg, Denmark
🇫🇷University Hospital CHU Nantes, Nantes, France
News
No news found